Current attitudes for therapy of febrile neutropenia with consideration to cost-effectiveness

Current Opinion in Oncology

Volumn 10, Issue 4, 1998, Pages 284-290

  Klastersky, Jean ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; ATTITUDE; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEVER; HOSPITAL COST; HUMAN; NEUTROPENIA; PRIORITY JOURNAL;

EID: 0031902659     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199807000-00002     Document Type: Article

References (24)

1. Bodey GP: The treatment of febrile neutropenia from the dark ages to the present. Support Care Cancer 1997, 5:351-357.
2. EORTC International Antimicrobial Therapy Cooperative Group: Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987, 317:1692-1698.
3. EORTC International Antimicrobial Therapy Cooperative Group: Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995, 40:1108-1115.
4. Freifeld AG, Walsh T, Marshall D, Gress J, Steinberg SM, Hathorn J, et al.: Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995, 13:165-176.
5. Elting LS, Rubenstein EB, Rolston KVI, Bodey GP: Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological clinical trials. Clin Infect Dis 1997, 25:247-259.
6. Viscoli C, Bruzzi E, Castagnola L, Boni L, Calandra T, Gaya H, et al.: Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. Eur J Cancer 1994, 30A:430-437. An attempt to identify factors predictive for Gram negative and Gram-positive sepsis in neutropenic patients.
7. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada - Clinical Trials Groups: Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991, 163:951-958.
8. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA: Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988, 108:30-35.
9. Talcott JA, Siegel RD, Finberg R, Godlman L: Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992, 10:316-322. Pivotal paper establishing the heterogeneity of the population of patients with febrile neutropenia.
10. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer: Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993, 119:584-593.
11. Sundararajan V, Rubenstein EB, Rolston KVI, et al.: Controversies in new antibiotic therapy for ambulatory patients. Support Care Cancer 1997, 5:358-364. A good review of present trends in ambulatory therapy of febrile neutropenia.
12. Hartmann LC, Tschetter LK, Habermann TM, Ebbert LP, Johnson PS, Maillard JA, et al.: Granulocyte colony stimulating factor in severe chemotherapy induced afebrile neutropenia. N Engl J Med 1997, 336:1776-1780.
13. Messori A, Trippoli S, Tendi E: G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation. J Clin Pharm Ther 1996, 21:57-63. Excellent analysis of the pharmacoeconomics of febrile neutropenia.
14. Geissler K, Koller E, Hubmann E, Neiderwiser D, Hinterberger W, Geisler D, et al.: Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia: a randomized phase III study. Blood 1997, 90:590-596.
15. Mitchell PLR, Morland B, Stevens MCG, Dick G, Easlea D, Meyer LC, et al.: Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 1997, 15:1163-1170.
16. Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, et al.: Filgrastim in patients with chemotherapy-induced febrile neutropenia. Ann Intern Med 1994, 121:492-501.
17. Vellenga E, Uyl-de Groot CA, de Wit R, Keiser HJ, Löwenberg B, ten Hafft MA, et al.: Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol 1996, 14:619-627.
18. Anaissie EJ, Vartivarian S, Bodey GP, Legrand C, Kantarijan H, Abi-Said D, et al.: Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-delivered) in cancer patients with fever and neutropenia. Am J Med 1995, 100:17-23.
19. Schimpff SC: Growth factors and empiric therapy with antibiotics: should they be used concurrently? Ann Intern Med 1994, 121:538-540.
20. Cruciani M, Rampazzo R, Malena M, Lazzari L, Todeschini G, Messori A, et al.: Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996, 23:795-805. A clear and comprehensive review of the controversial question of prophylaxis in neutropenic patients.
21. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, et al.: Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996, 14:636-643. Important study suggesting the need for further studies on factors predictive of the course of neutropenia after chemotherapy.
22. Rossi C, Klastersky J: Initial empirical antibiotic therapy for neutropenic fever: analysis of the causes of death. Support Care Cancer 1996, 4:207-212.
23. Klastersky J: Treatment of neutropenic infection: trends towards monotherapy? Support Care Cancer 1997, 5:365-370.
24. Murphy M, Brown AE, Sepkowitz KA, Bernard EM, Kiehn TE, Armstrong D: Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer - is it justified? Clin Infect Dis 1997, 25:346-347.